Ziprasidone

Summary

Ziprasidone (CHEMBL708) is an approved small-molecule psychotropic drug (ATC N05AE04) targeting HTR7, HTR1A, and DRD2; indicated across 15 conditions including psychotic disorder and schizoaffective disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AE04
• Targets: 11 (HTR7, HTR1A, DRD2…)
• Indications: 15 conditions
• Clinical trials: 108
• Chemistry: 412.9 Da · C21H21ClN4OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL708
Name	Ziprasidone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60854
ChEBI	CHEBI:10119
ATC	N05AE04
Molecular formula	C21H21ClN4OS
Molecular weight	412.9
InChIKey	MVWVFYHBGMAFLY-UHFFFAOYSA-N

SMILES: C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54

IUPAC name: 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one

ChEBI definition: A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.

Pharmacological roles (ChEBI): psychotropic drug, histamine antagonist, muscarinic antagonist, serotonergic antagonist, dopaminergic antagonist, antipsychotic agent.

Also known as: CP-88059, Zipradon, Ziprasidona, Ziprasidone, ziprasidone, SID26719835, SID144205747, SID144207074, ZIPRASIDONE, SID170465342

Parent form; salt/anhydrous children: CHEMBL1375743, CHEMBL3989833

Patent coverage: 5,393 distinct patent families (21,536 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 21,392 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR7	5-HT7 receptor	Inverse agonist	8.4	0.8%	P34969
HTR1A	5-HT1A receptor	Partial agonist	8.9	0%	P08908
DRD2	D2 receptor	Antagonist	8.55	0%	P14416
HRH1	H1 receptor	Antagonist	7.8	0%	P35367
HTR1B	5-HT1B receptor	Full agonist	8.3	0.2%	P28222
HTR1D	5-HT1D receptor	Full agonist	9	0%	P28221
HTR1E	5-ht1e receptor	Full agonist	6.4	0%	P28566
HTR2A	5-HT2A receptor	Antagonist	9.51	0%	P28223
HTR2C	5-HT2C receptor	Inverse agonist	9.01	0%	P28335
SLC6A2	NET	Inhibition	7.32	0.4%	P23975
SLC6A4	SERT	Inhibition	7.28	0.7%	P31645

Broader ChEMBL bioactivity targets: 44 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 138 potent at pChembl ≥ 5 of 145 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2A	10.1	Ki	0.08	nM	CHEMBL_ACT_2075811
HTR2A	9.6	Ki	0.25	nM	CHEMBL_ACT_694742
HTR2A	9.55	Ki	0.28	nM	CHEMBL_ACT_16312068
HTR2A	9.55	Ki	0.28	nM	CHEMBL_ACT_26580330
HTR2A	9.52	Ki	0.3	nM	CHEMBL_ACT_434838
HTR2A	9.41	Ki	0.39	nM	CHEMBL_ACT_2577190
HTR2A	9.4	Ki	0.4	nM	CHEMBL_ACT_13828633
HTR2A	9.38	IC50	0.42	nM	CHEMBL_ACT_1617790
P14842	9.38	Ki	0.42	nM	CHEMBL_ACT_495499
P14842	9.38	Ki	0.42	nM	CHEMBL_ACT_495502
P43140	9.3	Ki	0.5	nM	CHEMBL_ACT_2075859
HTR2A	9.3	AC50	0.5	nM	CHEMBL_ACT_25173726
HTR2C	9.26	Ki	0.55	nM	CHEMBL_ACT_694743
HTR2A	9.2	Ki	0.63	nM	CHEMBL_ACT_1925231
HTR2C	9.14	Ki	0.72	nM	CHEMBL_ACT_2577206
DRD2	9.1	Ki	0.8	nM	CHEMBL_ACT_18653019
DRD2	9.07	Ki	0.85	nM	CHEMBL_ACT_19047094
DRD2	9.05	Ki	0.9	nM	CHEMBL_ACT_19047099
DRD2	9.05	Ki	0.9	nM	CHEMBL_ACT_19216844
HTR2C	8.9	Ki	1.26	nM	CHEMBL_ACT_1925257
HTR2C	8.89	Ki	1.3	nM	CHEMBL_ACT_13828635
HTR2B	8.8	Ki	1.58	nM	CHEMBL_ACT_1924793
HTR1A	8.8	Ki	1.58	nM	CHEMBL_ACT_1925222
HTR2A	8.77	Ki	1.7	nM	CHEMBL_ACT_18653172
ADRA1D	8.72	Ki	1.9	nM	CHEMBL_ACT_694744
HTR1A	8.7	Ki	2	nM	CHEMBL_ACT_18653223
DRD2	8.68	Ki	2.1	nM	CHEMBL_ACT_17977958
DRD2	8.68	Ki	2.1	nM	CHEMBL_ACT_18899365
HTR1A	8.6	Ki	2.5	nM	CHEMBL_ACT_2577174
DRD2	8.55	Ki	2.8	nM	CHEMBL_ACT_694738

Target pathways

Aggregated over 11 target gene(s): HTR7, HTR1A, DRD2, HRH1, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, SLC6A2, SLC6A4.

Top Reactome pathways

25 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	7	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
Signaling by GPCR	7	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
Class A/1 (Rhodopsin-like receptors)	7	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
Amine ligand-binding receptors	7	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
Serotonin receptors	7	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
GPCR ligand binding	7	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
GPCR downstream signalling	6	HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
G alpha (q) signalling events	3	HRH1, HTR2A, HTR2C
G alpha (i) signalling events	3	HTR1B, HTR1D, HTR1E
SLC-mediated transport of neurotransmitters	2	SLC6A2, SLC6A4
Neurotransmitter clearance	1	SLC6A4
Transmission across Chemical Synapses	1	SLC6A4
Neuronal System	1	SLC6A4
Disease	1	SLC6A2
Serotonin clearance from the synaptic cleft	1	SLC6A4
Transport of small molecules	1	SLC6A2
Histamine receptors	1	HRH1
Dopamine receptors	1	DRD2
G alpha (s) signalling events	1	HTR7
R-HSA-425366	1	SLC6A2
SLC-mediated transmembrane transport	1	SLC6A2
SLC transporter disorders	1	SLC6A2
Defective SLC6A2 causes orthostatic intolerance (OI)	1	SLC6A2
Disorders of transmembrane transporters	1	SLC6A2
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
chemical synaptic transmission	9
signal transduction	9
G protein-coupled receptor signaling pathway	9
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	8
vasoconstriction	4
G protein-coupled serotonin receptor signaling pathway	4
adenylate cyclase-inhibiting serotonin receptor signaling pathway	4
response to xenobiotic stimulus	4
phospholipase C-activating serotonin receptor signaling pathway	4
serotonin receptor signaling pathway	3
regulation of behavior	3
adenylate cyclase-activating G protein-coupled receptor signaling pathway	3
intracellular calcium ion homeostasis	3
phospholipase C-activating G protein-coupled receptor signaling pathway	3
behavioral response to cocaine	3

Indications & clinical

Indications

15 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407
schizoaffective disorder	4	MONDO:0005487	EFO:0005411
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
bipolar disorder	3	MONDO:0004985	MONDO:0004985
autism	2	MONDO:0005260	EFO:0003758
mood disorder	2	MONDO:0005371	EFO:0004247
social phobia	2	MONDO:0001247	EFO:1001917
borderline personality disorder	2	MONDO:0001156	HP:0012076
major depressive disorder	2	MONDO:0002009	MONDO:0002009
cardiovascular disorder	1	MONDO:0004995	EFO:0000319
opiate dependence	0	MONDO:0005530	EFO:0005611
drug dependence	0	MONDO:0005303	EFO:0003890

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 108.

Phase distribution

Phase	Trials
PHASE4	45
PHASE3	28
Not specified	16
PHASE2	11
PHASE1	3
PHASE2/PHASE3	2
EARLY_PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048802	PHASE4	COMPLETED	Treatment and Outcome of Early Onset Bipolar Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00181922	PHASE4	COMPLETED	Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
NCT00199940	PHASE4	COMPLETED	Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
NCT00208208	PHASE4	COMPLETED	Geodon (Ziprasidone) for Posttraumatic Stress Disorder
NCT00224315	PHASE4	COMPLETED	Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
NCT00237666	PHASE4	COMPLETED	Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
NCT00239109	PHASE4	COMPLETED	Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.
NCT00330863	PHASE4	COMPLETED	Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
NCT00351000	PHASE4	COMPLETED	Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
NCT00374543	PHASE4	TERMINATED	Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
NCT00406315	PHASE4	COMPLETED	Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
NCT00418171	PHASE4	COMPLETED	Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
NCT00458211	PHASE4	COMPLETED	Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
NCT00472641	PHASE4	COMPLETED	Geodon in Weight Loss Study for Bipolar Disorders
NCT00622739	PHASE4	COMPLETED	Ziprasidone in Pediatric Bipolar Disorder
NCT00634348	PHASE4	COMPLETED	A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
NCT00644800	PHASE4	COMPLETED	A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
NCT00645320	PHASE4	COMPLETED	A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
NCT00649064	PHASE4	COMPLETED	A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
NCT00650429	PHASE4	COMPLETED	A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT00748566	PHASE4	TERMINATED	One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
NCT00786318	PHASE4	WITHDRAWN	Ziprasidone vs Standard Therapy for Agitated Patients in the ED
NCT00932529	PHASE4	COMPLETED	Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
NCT01157559	PHASE4	COMPLETED	Efficacy and Safety With Ziprasidone in First-episode Psychosis
NCT01168674	PHASE4	COMPLETED	Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
NCT01172652	PHASE4	COMPLETED	Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
NCT01185743	PHASE4	COMPLETED	Antipsychotics and Gene Expression in Soft Tissues
NCT01198353	PHASE4	COMPLETED	Effectiveness of Ziprasidone for Patients With Schizophrenia
NCT01293825	PHASE4	COMPLETED	Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)
NCT01714011	PHASE4	COMPLETED	Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
NCT01844700	PHASE4	TERMINATED	1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
NCT01893229	PHASE4	UNKNOWN	Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
NCT02040883	PHASE4	UNKNOWN	Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
NCT02282085	PHASE4	UNKNOWN	Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia
NCT02305823	PHASE4	COMPLETED	Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 24 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

950 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
RISPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
RITANSERIN	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR2A, HTR2C, HTR7, SLC6A4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7, SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7, SLC6A4
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
SALMETEROL	ChEMBL	Phase 4 (approved)	DRD2, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
PENFLURIDOL	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
ASENAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR2A, HTR2C, SLC6A2, SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
HALOPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
PERPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
PROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
SERTINDOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR2A, HTR2C, SLC6A2, SLC6A4
TEGASEROD	ChEMBL	Phase 4 (approved)	DRD2, HTR1A, HTR1D, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
THIORIDAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
VILAZODONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR7, SLC6A2, SLC6A4
LYSERGIDE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
METERGOLINE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
NIGULDIPINE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1B, HTR2C, HTR7, SLC6A2, SLC6A4
PIZOTYLINE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
Pyrazinamide	PubChem	Approved	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
ERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR2A, HTR7
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
QUETIAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR2A, HTR2C, HTR7
RIZATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C
SUMATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR7
CARVEDILOL	ChEMBL	Phase 4 (approved)	DRD2, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2, SLC6A4
CISAPRIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A4
CLEMASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
DIBENZEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR7, SLC6A2, SLC6A4
DOMPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
DULOXETINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
EBASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
LURASIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7, SLC6A2
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4